For help on how to get the results you want, see our search tips.
41 results
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Authorisation status
Withdrawn Remove Withdrawn filter
-
List item
Human medicine European public assessment report (EPAR): Paglitaz
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2012,
, Revision: 1, Withdrawn, Last updated: 10/03/2016
-
List item
Human medicine European public assessment report (EPAR): Pioglitazone Krka
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2012,, Revision: 2, Withdrawn, Last updated: 26/09/2014
-
List item
Human medicine European public assessment report (EPAR): Repso
leflunomide, Arthritis, Rheumatoid, Arthritis, Psoriatic
Date of authorisation: 14/03/2011,, Revision: 11, Withdrawn, Last updated: 21/04/2016
-
List item
Human medicine European public assessment report (EPAR): Ribavirin BioPartners
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 06/04/2010,, Revision: 2, Withdrawn, Last updated: 06/05/2013
-
List item
Human medicine European public assessment report (EPAR): Ribavirin Mylan (previously Ribavirin Three Rivers)
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 10/06/2010,, Revision: 10, Withdrawn, Last updated: 23/11/2020
-
List item
Human medicine European public assessment report (EPAR): Rivastigmine 3M Health Care Ltd
rivastigmine, Alzheimer Disease
Date of authorisation: 03/04/2014,, Revision: 1, Withdrawn, Last updated: 18/09/2014
-
List item
Human medicine European public assessment report (EPAR): Rivastigmine Teva
rivastigmine, Dementia, Alzheimer Disease, Parkinson Disease
Date of authorisation: 17/04/2009,, Revision: 4, Withdrawn, Last updated: 27/09/2012
-
List item
Human medicine European public assessment report (EPAR): Sabervel
irbesartan, Hypertension
Date of authorisation: 13/04/2012,, Revision: 2, Withdrawn, Last updated: 29/06/2017
-
List item
Human medicine European public assessment report (EPAR): Sepioglin
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 09/03/2012,, Revision: 1, Withdrawn, Last updated: 18/07/2013
-
List item
Human medicine European public assessment report (EPAR): Taxespira (previously Docetaxel Hospira UK Limited )
docetaxel trihydrate, Stomach Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 28/08/2015,, Revision: 8, Withdrawn, Last updated: 15/10/2019
-
List item
Human medicine European public assessment report (EPAR): Topotecan Actavis
topotecan, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 24/07/2009,, Revision: 6, Withdrawn, Last updated: 07/03/2019
-
List item
Human medicine European public assessment report (EPAR): Topotecan Eagle
topotecan (as hydrochloride), Carcinoma, Small Cell Lung Carcinoma
Date of authorisation: 22/12/2011,, Revision: 2, Withdrawn, Last updated: 14/11/2014
-
List item
Human medicine European public assessment report (EPAR): Topotecan Teva
topotecan, Ovarian Neoplasms, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 21/09/2009,, Revision: 8, Withdrawn, Last updated: 13/07/2018
-
List item
Human medicine European public assessment report (EPAR): Zalmoxis
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Date of authorisation: 18/08/2016,
, Revision: 1, Withdrawn, Last updated: 14/02/2020
-
List item
Human medicine European public assessment report (EPAR): Zoledronic acid Teva Generics
zoledronic acid monohydrate, Osteoporosis, Osteitis Deformans
Date of authorisation: 27/03/2014,, Revision: 2, Withdrawn, Last updated: 08/08/2016
-
List item
Human medicine European public assessment report (EPAR): Zoledronic acid Teva Pharma
zoledronic acid, Osteoporosis, Osteitis Deformans, Osteoporosis, Postmenopausal
Date of authorisation: 15/08/2012,, Revision: 11, Withdrawn, Last updated: 12/12/2018